Evidence map›Paper›PMID 42273912›Full record

ArticleNucleic acids research2026

Exploiting conformational changes in a caffeine aptamer to engineer synthetic RNA devices.

Leon Kraus, Vincent J Gunawan, Robin Johannson, Sarah Hallstein, Sina Block, Gaynor A Campbell, Alya Alameen, Susan J Rosser, Adam A Mol, Beatrix Suess

Abstract read
In one paragraph

Article in Nucleic acids research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Leon KrausDepartment of Biology, Technical University of Darmstadt, Darmstadt 64287, Germany.ORCID 0000-0003-3682-4872
Vincent J GunawanDepartment of Biology, Technical University of Darmstadt, Darmstadt 64287, Germany.
Robin JohannsonDepartment of Biology, Technical University of Darmstadt, Darmstadt 64287, Germany.ORCID 0009-0005-4183-8613
Sarah HallsteinDepartment of Biology, Technical University of Darmstadt, Darmstadt 64287, Germany.ORCID 0009-0001-3484-4549
Sina BlockDepartment of Biology, Technical University of Darmstadt, Darmstadt 64287, Germany.
Gaynor A CampbellEdinburgh Genome Foundry, University of Edinburgh, Edinburgh EH9 3BF, United Kingdom.
Alya AlameenUK Centre for Engineering Biology at the Institute of Quantitative Biology, Biochemistry, and Biotechnology, School of Biological Sciences, University of Edinburgh, Edinburgh EH9 3FF, United Kingdom.
Susan J RosserMission Hub for Engineered Genetic Control Systems for Advanced Therapeutics, University of Edinburgh, Edinburgh EH9 3BF, United Kingdom.ORCID 0000-0002-2560-6485
Adam A MolMission Hub for Engineered Genetic Control Systems for Advanced Therapeutics, University of Edinburgh, Edinburgh EH9 3BF, United Kingdom.
Beatrix SuessDepartment of Biology, Technical University of Darmstadt, Darmstadt 64287, Germany.ORCID 0000-0001-8666-6716

Funding

Biotechnology and Biological Sciences Research Council BB/Y008545/1Deutsche Forschungsgemeinschaft SU402/13-1Deutsche Forschungsgemeinschaft TRR440 A03Royal Academy of Engineering
6 · The paper itself

Abstract

RNA devices, including riboswitches, aptazymes, and RNA-based biosensors, have become essential components in synthetic and molecular biology. These systems make use of RNA's modularity and structural diversity to build programmable tools for sensing, regulation, and cellular computation. To drive these systems, RNA aptamers usually need to undergo a conformational change upon ligand binding. However, the limited availability of such aptamers has restricted the development and application of RNA devices, particularly in mammalian systems. Traditional selection methods often prioritize high-affinity binding, resulting in a scarcity of conformation-switching aptamers. Here, we addressed this limitation by selecting a caffeine-binding aptamer with RNA Capture-SELEX and in vivo screenings. This aptamer functioned as a modular regulator of riboswitches and ribozymes in Saccharomyces cerevisiae and mammalian cells. Through new optofluidic screenings, we overcame throughput and sequence-function challenges inherent in ribozyme screening for mammalia. Additionally, a straightforward grafting method transformed the aptamer into a fluorogenic iSpinach aptasensor. This work demonstrates the successful selection of a modular and communicating aptamer for a challenging target like caffeine and establishes robust strategies for their modular integration into diverse RNA platforms. These strategies pave the way for broadening the repertoire of aptamers and expanding the potential of RNA-based synthetic biology.

Indexed as

Aptamers, NucleotideCaffeineAnimalsBiosensing TechniquesNucleic Acid ConformationRiboswitchRNA, CatalyticSaccharomyces cerevisiaeSELEX Aptamer TechniqueAptamers, NucleotideCaffeineRiboswitchRNA, Catalytic

Identifiers

PMID42273912
PMCPMC13254537

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.